Upexi, a Nasdaq-listed firm specializing in Solana-focused treasury management, has filed a shelf registration with the US Securities and Exchange Commission to potentially raise $1 billion. This filing allows the company to issue common stock, preferred shares, debt securities, warrants, or units over time, providing flexibility in capital raising.

With a portfolio that includes Cure Mushrooms and Lucky Tail, and holding over 2 million SOL tokens valued at $248 million, Upexi is poised to utilize any raised capital for various purposes including working capital, research, acquisitions, and debt repayment. The company's stock price fell by nearly 7% to $1.85 on Tuesday, contributing to a year-to-date loss of around 50%, while Solana has dropped by 34% over the same period.